Description
Opening Plenary Session | In this opening session, representatives from FDA and from industry will give their high-level perspective on where the Pharmaceutical Industry is heading. The COVID-19 crisis saw drastic changes in the way of working, but also tremendous efforts from the pharmaceutical industry to develop therapies and vaccines for SARS-Cov2 infections. Rapid development, commercial upscaling and distribution are needed to deliver to the patients. Ways of working need to be rethought, procedures developed and implemented at high speed.
Session Leader(s):
- Jörg
Zimmermann,
Vice President, Vetter Development Service, External Affairs,
Vetter Pharma-Fertigung GmbH & Co.
Speaker(s):
- Thomas
B. Hartman,
President and CEO,
ISPE
- Rick
Friedman,
Deputy Director, Office of Manufacturing Quality,
CDER/FDA
- Jean
Hu-Primmer,
Global Regulatory Lead,
GSK Vaccines
- Antonio
R. Moreira,
PhD,
Vice Provost, Academic Affairs,
University of Maryland, Baltimore County
- Joydeep
Ganguly,
Senior Vice President, Corporate Operations,
Gilead Sciences Inc
